All In Biotech

Drug Trial Radar · NCT03063086

Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

A Randomized, Double-blind, Double-dummy, Active-controlled, 3-period Complete Cross-over Study to Assess the Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma

Last checked: Nov 19, 2026Latest source record: Oct 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

116

Actual

Start

Jan 21, 2017

Primary completion

Aug 2, 2018

Study completion Aug 2, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess peak FEV1 of two doses of QVM149 compared to a fixed-dose combination of salmeterol/fluticasone (50/500μg b.i.d.) and to characterize the respective 24 hour bronchodilator effect profiles in patients with asthma. Data from this study will complement lung function data obtained in the pivotal QVM149 phase 3 program by assessing the bronchodilatory effect of QVM149 at multiple time-points over an entire dosing interval of 24 hours.

Conditions

  • Asthma

Interventions

  • QVM149 150/50/80 μg o.d.Drug

    A

  • QVM149 150/50/160 μg o.d.Drug

    B

  • salmeterol/fluticasone FDC 50/500 μg b.i.d.Drug

    C

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak FEV1 (L) Defined as the Highest Bronchodilatory Effect on FEV1 During a Period of 5 Min to 4 h After the Last Evening Dose of Each Treatment PeriodTime frame: 3 weeks

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Changchun, Jilin, China

  • Novartis Investigative Site

    Tianjin, Tianjin Municipality, China

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Großhansdorf, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Wiesbaden, Germany

  • Novartis Investigative Site

    Groningen, GZ, Netherlands

  • Novartis Investigative Site

    Bucharest, Romania

  • Novartis Investigative Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.